16.19
0.81%
+0.13
After Hours:
16.19
Regenxbio Inc stock is currently priced at $16.19, with a 24-hour trading volume of 301.90K.
It has seen a +0.81% increased in the last 24 hours and a -25.29% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $15.84 pivot point. If it approaches the $16.38 resistance level, significant changes may occur.
Previous Close:
$16.06
Open:
$16.2
24h Volume:
301.90K
Market Cap:
$794.00M
Revenue:
$90.24M
Net Income/Loss:
$-263.49M
P/E Ratio:
-2.5617
EPS:
-6.32
Net Cash Flow:
$-228.37M
1W Performance:
+3.19%
1M Performance:
-25.29%
6M Performance:
+5.47%
1Y Performance:
-12.01%
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9600 Blackwell Road, Suite 210, Rockville, MD
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-01-23 | Initiated | Stifel | Buy |
Jun-02-23 | Initiated | Robert W. Baird | Outperform |
Jun-23-22 | Initiated | Berenberg | Buy |
Dec-15-21 | Initiated | Wedbush | Neutral |
Oct-19-21 | Resumed | Morgan Stanley | Overweight |
Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
Dec-16-20 | Initiated | UBS | Buy |
Jun-25-20 | Resumed | BofA/Merrill | Buy |
May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
Jun-14-19 | Resumed | Raymond James | Outperform |
Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
May-09-18 | Reiterated | Barclays | Overweight |
Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
Feb-13-18 | Initiated | Mizuho | Neutral |
Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Where Regenxbio Stands With Analysts
Benzinga
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
Benzinga
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Zacks Investment Research
Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
Benzinga
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Regenxbio Inc Stock (RGNX) Financials Data
Regenxbio Inc (RGNX) Revenue 2024
RGNX reported a revenue (TTM) of $90.24 million for the quarter ending December 31, 2023, a -19.94% decline year-over-year.
Regenxbio Inc (RGNX) Net Income 2024
RGNX net income (TTM) was -$263.49 million for the quarter ending December 31, 2023, a +6.00% increase year-over-year.
Regenxbio Inc (RGNX) Cash Flow 2024
RGNX recorded a free cash flow (TTM) of -$228.37 million for the quarter ending December 31, 2023, a +4.13% increase year-over-year.
Regenxbio Inc (RGNX) Earnings per Share 2024
RGNX earnings per share (TTM) was -$6.02 for the quarter ending December 31, 2023, a +7.38% growth year-over-year.
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Cap:
|
Volume (24h):